EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?
Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...
Presence of Minimal Residual Disease Predicts Relapse and Survival in AML
For patients with acute myeloid leukemia (AML), the detection of molecular minimal residual disease (MRD) in patients achieving morphologic complete remission (CR) was associated...
Complete Mutation Clearance Predicts Longer Survival and Lower Relapse Risk in AML
Somatic mutation clearance (MC) at complete remission (CR) of acute myeloid leukemia (AML) was associated with improved survival and reduced risk of relapse, according...
NYC Firefighters Exposed to World Trade Center Disaster Have Increased Myeloma Risk
New York City firefighters who were exposed to chemicals released into the environment following the World Trade Center (WTC) attacks on September 11, 2001,...
Combination Ibrutinib, Carfilzomib, and Dexamethasone Is Promising for Relapsed/Refractory MM
In a phase I dose-finding study, two-thirds of patients with relapsed/refractory multiple myeloma (MM) responded to the triplet combination of ibrutinib plus carfilzomib and...
Individual Testing Effective, But Costly, in Screening for Zika Virus in Blood Donations
In March 2016, approximately one year after Zika virus (ZIKV) infections were reported in the United States, the U.S. Food and Drug Administration (FDA)...
Evaluating Daratumumab as Frontline Treatment of Transplant-Ineligible Myeloma
Results from a prespecified interim analysis from the phase III ALCYONE study found that the addition of daratumumab to standard care (bortezomib, melphalan, prednisone...
Study Finds Pharmaceutical Funding Influences Selection of Cancer Treatment
U.S. physicians and hospitals receive approximately $7 billion annually from the pharmaceutical industry. According to a research letter published in JAMA Internal Medicine, this...
Gene Therapy Alleviates Transfusion Burden in Patients With Beta-Thalassemia
Treatment with gene therapy reduced or eliminated the need for long-term red blood–cell (RBC) transfusions in some patients with severe, transfusion-dependent beta-thalassemia, according to...
Venetoclax Outperforms Standard Chemo-Immunotherapy in the Treatment of Relapsed/Refractory CLL
Treatment with the BCL2 inhibitor venetoclax and rituximab led to deeper and more durable responses than the combination of bendamustine and rituximab in patients...
Current Issue
July 2018 Bonus Mid-Year Edition
This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.
